institute for melanoma research & education › app › uploads ›...

Edward F. McClay

INSTITUTE FOR MELANOMA RESEARCH & EDUCATION

CURRICULUM VITAE Edward F. Mc Clay, M.D. February 27, 2014 Director Office: Institute for Melanoma Research & Education California Cancer Associates for Research & Excellence, Inc. 477 N. El Camino Real, Suite D-200 Encinitas, CA 92024 Date of Birth: 9/27/49 Place of Birth: Philadelphia, PA Citizenship: USA Marital Status: Married (Mary-Eileen); 2 children (Sean; Moira) EDUCATION: University 1967-1968 1971-1973 1973-1975 1976

B.A.

Temple University, Philadelphia, PA University of Arizona, Tucson, AZ Wright State University, Dayton, OH Temple University; Philadelphia, PA

Medical School 1976-1977 1977-1980

M.D.

Thomas Jefferson University Philadelphia, PA Temple University School of Medicine, Philadelphia, PA

Internship 7/80-6/81

Tucson Hospitals Medical Education Program, Internal Medicine, Tucson, AZ

Residency 7/81-6/83

Thomas Jefferson University Internal Medicine Philadelphia, PA

Fellowship 7/84-6/86

Thomas Jefferson University Medical Oncology, Philadelphia, PA

Board Certification Diplomate, National Board of Medical Examiner, 1981

Edward F. McClay

Diplomate, American Board of Internal Medicine, 1984 Diplomate, American Board of Internal Medicine, Medical Oncology, 1989 Licensure Pennsylvania MD-025979-E (Inactive) California G-064594 (Active) South Carolina 16965 (Inactive) Military Service United States Air Force, Staff Sergeant-Ballistic Missile Systems Analyst Technician. Honorable Discharge 1969-1975 Faculty Appointments 1983-1984

Clinical Instructor

Medicine

Thomas Jefferson University Philadelphia, Pennsylvania

1986-1988

Clinical Asst. Professor

Medicine Oncology

Thomas Jefferson University Philadelphia, Pennsylvania

1988-1993

Asst. Adjunct Professor

Medicine Oncology

University of California San Diego, CA

1993 Assoc. Adjunct Professor Medicine Oncology

University of California San Diego, California

10/93-12/98

Associate Professor

Medicine Hem/Onc

Medical University of South Carolina Charleston, South Carolina

1/99-7/01

Professor of Medicine

Medicine Hem/Onc

University of California, San Diego San Diego, California

7/03-2004 Clinical Professor of Medicine University of California, San Diego Medicine Hem/Onc San Diego, California Private Practice 7/01-7-03 Director San Diego Melanoma Research Center/Medical Group of

North County, Vista CA 7/03-Present Director Institute for Melanoma Research & Education/ San Diego

Pacific Oncology & Hematology Associates, Encinitas, CA

Edward F. McClay

Hospital Appointments 1997-1998 Chairman, Cancer IDT Medical University of South Carolina 1994-1997 Cancer Committee Medical University of South Carolina Administrative Appointments 1999-2001

Associate Director for Clinical Affairs

Division of Hematology/Oncology Univ. of California, San Diego

1999-2001 Cancer Center Business Planning Cancer Center Univ. of California, San Diego

1999-2001

Cancer Center Building Advisory Committee

Cancer Center Univ. of California, San Diego

1999-2001

Chairman, Clinical Trials Database Selection Committee


1999-2001

Oncology Task Force


1999-2001

Cancer Center Activities Review Group


1999-2001

Cancer Center Clinical Operations


1996-1998 Medical Director Hollings Cancer Center Medical Univ. of South Carolina

1996-1998

Chairman, HCC Operations Committee

Hollings Cancer Center Medical Univ. of South Carolina 1996-1997 Interim Director Div. Hem/Onc Department of Medicine Medical Univ. of South Carolina

1995-1998 Chairman, Protocol Review Committee Hollings Cancer Center Medical Univ. of South Carolina

1993

Ad Hoc Committee on Gene Transfer

Univ. of California, San Diego

1990-1992

Director, Outpatient Clinic Cancer Center


1990-1991

Chairman, Oncology Clinical Program & Operation Planning Sub-committee

Cancer Center Univ. of California, San Diego 1990-1993

Oncology Task Force


1988-1993

Clinical Trials Computerization Committee


Edward F. McClay

1988-1993

Clinic Oversight Committee


Awards, Honors • Seventh Annual Chief Residents Teaching Award, University of California, San

Diego June 2, 1993 • Certificate of Recognition, California State Assembly, June 22, 2000

Society Memberships

• American Society of Clinical Oncology • American Association for Cancer Research • American Association for the Advancement of Science • Southern Medical Association

Ad Hoc Editorial Review

• Journal of Clinical Investigation • Cancer Research • Journal of the American Academy of Dermatology • Journal of Clinical Oncology • Molecular Pharmacology • American Journal of Clinical Oncology

Extramural Grant Support SmithKline Beecham 9/23/99-9/22/2000 3% effort (PI) Direct: $33,473 Total: $40,000 Title: Phase I/II Trial of Hycamptin in Combination with Cranial Irradiation for the

Treatment of Patients with Brain Metastases Pharmacia & Upjohn 7/1/99-7/1/2000 5% effort (PI) Direct: $58,577 Total: $70,000 Title: A Phase II Trial of CPT-11 in Patients with Advanced Malignant Melanoma RO1-CA52151 5/1/90-4/30/93 30% effort (PI) NIH/NCI Modulation of Cisplatin Resistance in Malignant Melanoma Direct $586,375 Total $873,660 RO1-CA52151 5/1/93-4/30/97 40% effort (PI) NIH/NCI Modulation of Cisplatin Resistance in Malignant Melanoma Direct $607,164 Total $906,771 Cancer Research Institute 9/1/97-8/30/99 10% effort (Co-Investigator) Semi-allogenic hybrids as cancer vaccines Academic Committees

Edward F. McClay

1999-2001

Chair, Lung Cancer Medical Oncologist Search Committee


1999-2001

G.U. Faculty Search Committee Ad Hoc Committee on Faculty Productivity Intern Selection Committee Fellow Selection Committee


1989-1993 Oncology Fellowship Selection Committee Univ. Of California, San Diego 1989-1993

Recruitment and Admissions Committee

School of Medicine Univ. of California, San Diego

1986-1987

Intern Selection Committee; Medicine

Thomas Jefferson University Philadelphia, PA

Major Teaching Responsibilities Undergraduate: Physical Diagnosis Graduate Studies: Biology of Neoplasia Immunotherapy of Cancer Molecular Basis for the Treatment of Cancer Major Clinical Interests and Responsibilities

• Director, Institute for Melanoma Research & Education Meetings

• Course Director -- Current Strategies for the Treatment of Patients with Malignant Melanoma, South East Regional Meeting Charleston, SC March 11, 1995

Invited Lectures Pre-Operative Evaluation of the Jefferson Medical College. 1988 Oncology Patient. Philadelphia, Pennsylvania Update on Intraperitoneal Chemotherapy. University of California, Cancer 1989 Center, San Diego, California Intraperitoneal Chemotherapy in University of California, San Diego 1989 the Treatment of Ovarian Cancer. San Diego, California Carboplatin and Etoposide in the Joint US-Japan Conference on 1989 Treatment of Intraperitoneal Malignancies Cancer Therapeutics, USC Los Angeles, California

Edward F. McClay

Intraperitoneal Chemotherapy in San Diego Gynecologic Society 1989 the Treatment of Ovarian Cancer. San Diego, California Intraperitoneal Chemotherapy, a review. Mayo Clinic. Phoenix, Arizona 1989 A Phase I and Pharmacokinetic Study 4th International Congress on Local of Carboplatin and Etoposide and Regional Therapy of Cancer. Administered via the Intraperitoneal Bergstangander, West Germany 1989 Route. Intraperitoneal Chemotherapy for Ovarian Miami Regional Oncology Society. 1989 Cancer. Miami, Florida Intraperitoneal Chemotherapy for Intra- Long Beach Memorial Hospital 1989 abdominal malignancies. Long Beach, California Therapeutic Effectiveness of Carboplatin. Phoenix Oncology Society 1989 Phoenix, Arizona Malignant Melanoma: Mayo Clinic Hospital 1989 Update on New Therapy. Phoenix, Arizona Ovarian Cancer, A Review. Sansum Cancer Center 1990 Santa Barbara, California Therapeutic Advances in the Treatment University of California, San Diego 1990 of Malignant Melanoma. San Diego, California Malignant Melanoma. An Update Long Beach Memorial Hospital 1990 Long Beach, California, Malignant Melanoma for the Dermatologist University of California, San Diego 1990 San Diego, California, Pre-Operative Evaluation of the Jefferson Medical College. 1990 Oncology Patient. Philadelphia, Pennsylvania Intraperitoneal Cisplatin and Carboplatin Western Memorial Hospital 1990 for Ovarian Cancer. Los Angeles, California Advances in the Diagnosis and Treatment Presbyterian Memorial Hospital. 1990 of Malignant Melanoma. Los Angeles, California Ovarian Cancer Update. Advances in the Memorial Regional Cancer Center 1990 Treatment of Cancer in Women. Modesto, CA

Edward F. McClay

Advances in the Treatment of University of California, Irvine 1990 Malignant Melanoma Cancer Center, Irvine, California, Adjuvant Therapy for the Treatment of. Scripps Clinic and Research Institute 1991 Bone and Soft Tissue Sarcomas. La Jolla, CA. Adjuvant Therapy for Colorectal Cancer. University of California, San Diego 1991 Topics in Internal Medicine. San Diego, California Dysplastic Nevi and Melanoma. Salk Institute 1991 Updates in Medicine Sponsored by the La Jolla, California Italian Medical Society, Italy

Intraperitoneal Therapy for Ovarian Saint Bernadine, Cancer Center 1991 Cancer San Bernadino, California Modulation of Cisplatin Resistance by National Cancer Institute 1991 Tamoxifen. NCI Working Group: Bethesda, Maryland Multiple Drug Resistance Therapeutic Advances in the Treatment Department of Medicine 1991 of Melanoma, Medical Grand Rounds University of California, San Diego. Role of Tamoxifen in the Treatment of Medical Grand Rounds 1995 Malignant Melanoma Medical University of South Carolina Malignant Melanoma; Current Therapy Greenville/Spartanburg Hospitals 1995 System, Greenville, SC Malignant Melanoma; Current Therapy Florence Hospital 1995 Florence, South Carolina Malignant Melanoma, Current Treatment Southern Oncology Association 1996 Charleston, South Carolina New Approaches to the Treatment of South Carolina Dermatology Assoc 1998 Malignant Melanoma Charleston, South Carolina Current Therapy for Malignant Melanoma Columbia Oncology Association 1998 Columbia, South Carolina Current Therapy for Malignant Spartanburg Oncology Association 1998 Melanoma Spartanburg, South Carolina

Edward F. McClay

Current Therapy for Malignant Augusta Oncology Association 1998 Melanoma Augusta, Georgia Malignant Melanoma: New Strategies Medical College of Georgia, Medical 1998 New Treatments Grand Rounds, Augusta, GA New Advances in Melanoma Clemson Symposium 1998 Clemson, South Carolina Clinical Advances in Malignant San Diego Oncology Clinical Trials 1999 Melanoma Group San Diego, CA Novel Concepts in the Treatment of Salik Health Care, Mount Siani 1999 Malignant Melanoma Melanoma Program, Miami, FL New Approaches to the treatment of Preceptorship in Dermatology 1999 Malignant Melanoma University of California, San Diego Advances in the Treatment of 24th Annual San Diego Postgraduate 2001 Malignant Melanoma Assembly in Surgery University of California, San Diego Update in Malignant Melanoma Scripps Memorial Hospital, LaJolla 2002 LaJolla, CA Advances in the Treatment of Upper 26th Annual Oncology for the General 2003 GI and Pancreatic Malignancies Surgeons University of California, San Diego Advances in the Treatment of Colon 26th Annual Oncology for the General 2003 and Rectal Cancers Surgeons University of California, San Diego Malignant Melanoma for the Primary Scripps Memorial Hospital, Encinitas 2003 Care Physician Encinitas, CA Colo/rectal Cancer for the Primary Scripps Memorial Hospital, Encinitas 2003 Care Physician Encinitas, CA Advances in Malignant Melanoma Scripps Memorial Hospital, LaJolla 2004 LaJolla, CA Melanoma for the Primary Care Scripps Memorial Hospital, Encinitas 2005 Physician Encinitas, CA Malignant Melanoma, Update Scripps Memorial Hospital, LaJolla 2006

Edward F. McClay

LaJolla, CA Melanoma for the Primary Care Tri-City Hospital, Vista, CA 2006 Physician Molecular Biology of Cancer Tri-City Hospital, Vista CA 2008 Genetics of Colo/rectal Cancer Scripps Coastal Medical Group 2009 Vista CA Advances in Melanoma Scripps Health Foundation 2011 Distinguished Speakers Series Melanoma, Update for the Primary Fallbrook Hospital, Fallbrook, CA 2011 Care Physician Novel Therapies for melanoma Genentech Speakers Bureau 2012/13 Patients with V600E mutations 20 Sites throughout US Novel Therapies for Patients wth Genentech Speakers Bureau 2012/13 Metastatic Basal Cell Cancer 20 Sites throughout US Abstracts 1. Slovin SF, Lackman RD, Ferrone S, Mc Clay EF, Weiss AJ, Mastrangelo MJ.

Analysis of cellular immune response to sarcomas using cytotoxic T cell clones. Proc AACR 27: 360, 1986

2. Mc Clay EF, Mastrangelo MJ, Bellet RE, Berd D. An effective chemo/hormonal

therapy regimen for the treatment of disseminated malignant melanoma. Proc ASCO 6: #821, 208 1987

3. Mc Clay EF, Sprandio JD, Mastrangelo MJ, Bellet RE, Berd D. Importance of

Tamoxifen to a combination chemotherapy regimen for melanoma. Proc ASCO 7: #971, 251, 1988

4. Mc Clay EF, Mastrangelo MJ, Bellet RE, Berd D. An effective chemo/hormonal

therapy regimen for the treatment of disseminated malignant melanoma. Update I. Proc ASCO 8: #1058, 1989

5. Mc Clay EF, Kirmani S, Kim S, McVey L, Howell SB. A phase I trial of intraperitoneal Carboplatin (CBDCA) and Etoposide (VP-16). Proc. ASCO 8: 301, 1989.

6. Mc Clay EF, Goel R, Kirmani S, McVey L, Kim S, Braly P, Plaxe S, Alcaraz J,

Hoff S, Howell SB. A phase I pharmacokinetics study of Carboplatin and Etoposide administered via the intraperitoneal route. Proc. ASCO 9: 332, 1990.

Edward F. McClay

7. Kim S, Mc Clay EF, Kirmani S, Goel R, McVey L, Plaxe S, Braly P, Howell SB.

Biweekly intravenous Cisplatin with Sodium Thiosulfate. Proc ASCO: 333, 1990 8. Mc Clay EF, Kirmani S, Kim S, Braly P, Plaxe S, McClay ME, Wilgus L, Hoff

S, Howell SB. Phase I trial of high dose carboplatin (CBDCA) and VP-16 via the intraperitoneal route with human recombinant granulocyte macrophage-colony stimulating factor (GM-CSF) support. Proc ASCO 10: 255, 1991

9. Huberman M, Mc Clay EF, Atkins M, Goldswieg H, Bonanno D, Layton M,

Tessitore J. Phase II trial of 5 Fluorouracil (5FU) and recombinant interferon-Alpha-2A (IFN) in advanced colorectal cancer. Proc ASCO 10: 478, 1991

10. Goel R, Mc Clay EF, Kirmani S, Kim S, Braly PF, Plaxe SC, Alcaraz J, Andrews

PA, Reichman B, Markman M, Howell SB. Pharmacokinetics study of intraperitoneal streptozotocin. Proc AACR 32: 1032, 1991

11. Mc Clay EF, Albright K, Jones J, Christen R, Howell SB. Modulation of

Cisplatin (DDP) sensitivity by tamoxifen (TAM) in human malignant melanoma. Proc ASCO 10: #1017, 291, 1991.

12 Mc Clay EF, Albright K, Jones J, Christen R, Howell SB. Modulation of

Cisplatin resistance by Tamoxifen in malignant melanoma. Advances in biology and clinical management of melanoma. The Twenty-fifth annual Clinical Conference and Twenty-fourth annual Special Pathology Program. M.D. Anderson Cancer Center, Houston, Texas #7, 1991.

13. Christen RD, Mc Clay EF, Wilgus LL, Shalinsky D, Heath D, Howell SB. In

vivo modulation of doxorubicin by high dose progesterone. A phase I/pharmacokinetics study. Proc ASCO 11: #304, 121, 1992

14. Kirmani S, Mc Clay EF, Kim S, Braly P, Plaxe S, Howell SB. A phase I trial of

concurrent intraperitoneal Cisplatin and Carboplatin. Proc ASCO 11: #336, 129, 1992

15. Plaxe S, Braly P, Mc Clay EF, Kirmani S, Kim S, Howell SB. Prognosis of very

young patients (<30 years of age) with epithelial ovarian cancer. Proc ASCO 11: #721, 227, 1992

16. Plaxe S, Braly P, Mc Clay EF, Kirmani S, Kim S, Howell SB. Outcome of five

year survivors with ovarian carcinoma. Proc ASCO 11: #761, 237, 1992 17. Mc Clay EF, Albright K, Jones J, Christen R, Howell SB. Modulation of

Cisplatin (DDP) resistance by tamoxifen (TAM) in human malignant melanoma. Proc AACR 33: 536, 1992

Edward F. McClay

18. Mc Clay EF, Mc Clay ME, Albright KA, Jones J, Christen R, Howell SB Modulation of Cisplatin resistance by tamoxifen in malignant melanoma. Proc ASCO 11: #1176, 343, 1992

19. Howell, S.B., Mc Clay EF., Jones, J., Albright, K.:Tamoxifen (TAM)

synergistically enhances the sensitivity of a human malignant melanoma cell line to cisplatin (DDP) and carboplatin (CBDCA). NCI-EORTC 1992

20. Mc Clay EF, Albright K, Jones J, Christen R, Howell SB. N, N-diethyl-2-[(4-

phenylmethyl)-phenoxyl]-ethanamine HCL (DPPE) is synergistic with cisplatin (DDP) in human melanoma cells. Proc AACR 34:402, 1993

21. Mc Clay EF, Albright K, Jones J, Christen R, Howell SB. Tamoxifen (TAM)

delays the development of resistance to cisplatin (DDP) in human malignancies. Proc ASCO 12: #326, 132, 1993

22. Christen RD, Mc Clay EF, Plaxe SC, Freddo JL, Braly PS, Kim S, Kirmani S,

Qvistgaard D, Heath DD, Shalinsky DR, Howell SB. In vivo modulation of doxorubicin by progestational agents. Proc ASCO 12: #392, 148, 1993

23. Jones JA, Gately DP, Albright KD, Christen RD, Mc Clay EF, Howell SB.

Induction of GADD 153 in human ovarian and human melanoma xenografts as an indicator of genotoxic injury. Proc ASCO 12: #244, 111, 1993

24. Plaxe S, Braly P, Freddo J, Mc Clay EF, Kirmani S, Kim S, Christen R, Heath D,

Howell SB. Phase I trial of intraperitoneal (ip) ormaplatin (OP) with extended pharmacokinetics (pk) assessment. Proc AACR 34:402, 1993

25. Plaxe S, Christen R, O'Quigley J, Braly P, Freddo J, Mc Clay EF, Heath D,

Howell SB. Phase I trial of intraperitoneal Topotecan. Proc ASCO 12: #360, 140, 1993

26. Kirmani S, Braly P, Mc Clay EF, Saltzstein S, Plaxe SC, Kim S, Cates C, Howell

SB. A phase III trial comparing intraperitoneal (IP) versus intravenous (IV) chemotherapy for ovarian cancer. Proc ASCO 12: #865, 270, 1993

27. Christen RD, Mc Clay EF, Mason J, Plaxe SC, Braly PS, Vicario D, Kirmani S,

Kim S, Qvistgaard D, MacManus D, Heath D, Mullan M, Howell SB:In vitro and in vivo modulation of P-glycoprotein activity by progestational agents. Proc AACR 35:270 (1237), 1994

28. Mc Clay EF, Albright KD, Jones JA, Christen RD, Howell SB: Tamoxifen

(T)/cisplatin (DDP) synergy may be mediated via anti-estrogen binding sites (AEBS). Proc ASCO 13: #1356, 398, 1994

29. Mc Clay EF, Mc Clay ME, Jones JA, Winski PJ: A phase I trial of high dose

Edward F. McClay

tamoxifen (TAM) and weekly cisplatin (DDP) in the treatment of metastatic melanoma. Proc ASCO 14: #1300, 411, 1995.

30. Christen, E.D., Kirmani, S., D’Agostino, H.R., Plaxe, S., Darrah, D., Mc Clay

EF., Howell, S.B.: Correlation between tumor response and change in GADD153 mRNA level in human biopsies after paclitaxel treatment. Proc ASCO 15: #571, 233, 1996

31. Aebi S, Los G, Kirmani S, McClay EF, D’Agostino H, Plaxe S, Darrah D, Heath

D, Howell SB, Christen RC: High dose progesterone (P) enhances the therapeutic effect of Paclitaxel (TAX). Proc ASCO 15: #1557, 488, 1996

32. Kayaleh O, Mc Clay ME, Kneuper-Hall R, Mc Clay EF: A Phase II trial of high

dose tamoxifen (TAM) and cisplatin (DDP) for patients with malignancies. Proc ASCO 15: #408, 191, 1996

33. Mc Clay EF, Mc Clay ME, Jones JA, Winski PJ, Hall PD: A Phase II trial of

high dose tamoxifen (TAM) and weekly cisplatin (DDP) for patients with metastatic melanoma. Proc ASCO 15: #1351, 435, 1996

34. Jones JA, Albright KD, Winski PJ, Christen RD, Howell SB, Mc Clay EF: Loss

of high affinity nuclear anti-estrogen binding site confers loss of synergy between cisplatin and tamoxifen in human melanoma cells. Proc AACR 37: #243, 35, 1996

35. McClay EF, Winski PJ, Jones JA, Jenrette, III, JM, Gattoni-Celli S: ∆12-PGJ2 is

cytotxic alone and synergizes in combination with both cisplatin and radiation in human malignancies. Proc AACR 37: #2696, 395, 1996

36. Cole DJ, Gattoni-Celli S, Mc Clay EF, Nabavi N, Warner SN, Newton D,

Woolhiser C, Wilson M, Vournakis J: Characterization of a sustained release delivery system for combined cytokine/peptide based vaccination using a fully-acetylated ploy-N-acetyl glucosamine matrix. Proc AACR 37: #3262, 478, 1996

37. Newton DA, Mc Clay EF, Broderick CW, Gattoni-Celli S: Melanoma cell

hybrids as cancer vaccines. Proc AACR 38: #2671, 1997 38. Mc Clay EF, Jones JA: Tamoxifen (TAM) resistance is associated with decreased

p27 expression and reduction in TGF-ß1 production. Proc AACR 38: #4193, 624, 1997

39 McClay EF, Mc Clay ME, Baron P, Cole D, O’Brian P, Metcalf J, Maize J:

Tamoxifen (TAM) and cisplatin (DDP) effect on the disease free survival (DFS) and overall (OS) in patients with surgically resected metastatic melanoma. Proc ASCO 16: #1824, 507a, 1997

Edward F. McClay

40 Rocha-Lima CM, Jones JA, Mc Clay EF: Interleuikin-2 augments the in vitro production of nitric oxide in human macrophages pretreated with cisplatin. Proc ASCO 16: #1593, 444a, 1997

41. Mc Clay EF, Jones JA, Wang L-M, Gattoni-Celli S: ∆12-Prostaglandin J2 (∆12-

PGJ2)/cisplatin (DDP) synergy in human melanoma cells (T-289) is mediated via an apoptotic mechanism. Proc AACR 39: #1070, 157, 1998

42. Wang LM, Jones JA, Mc Clay EF: ∆12-Prostaglandin J2 (∆12-PGJ2) induction of

multinucleation and apoptosis in human prostate cancer cells (PC3) is associated with a reduction in cdc-2 and an increase in cyclin A. Proc AACR 39: #1069, 157, 1998

43. Milito SJ, Brunson CY, Baron PL, Hoffman BJ, LaVeen P, Turrisi AT, Mc Clay

EF: Conformal radiation therapy and concomitant cisplatin (DDP)/high dose tamoxifen (HD-TAM). Proc AACR 39: #3424, 503, 1998

44. Mc Clay EF, Mc Clay ME, Monroe L, Baron P, Cole D, O’Brien P, Metcalf J,

Maize J: The effect of tamoxifen (TAM) and cisplatin (DDP) on the disease free survival (DFS) and overall survival (OS) in patients with surgically resected metastatic melanoma Proc ASCO 17: #2006, 522a, 1998

45. Brunson CY, Baron P, Milito S, Featherston P, Mc Clay EF: Phase I trial of

weekly low dose cisplatin (DDP) escalating tamoxifen (TAM) and conformal radiation (XRT) therapy in the treatment of locally advanced/unresectable pancreatic cancer. Proc ASCO 17: #907, 236a, 1998

46. Rocha-Lima CM, Kayaleh O, Mc Clay EF: Phase II Trial of Cisplatin and

Tamoxifen (CisTam) in Metastatic Solid Tumors. Proc ASCO 18: #753, 196a, 1999

47. Brunson CY, Baron P, Leveen P, Milito S, and Mc Clay EF: Phase I Study of

Escalating Tamoxifen (TAM), Weekly Low Dose Cisplatin (cDDP), and Conformal Radiation Therapy (XRT) in Patients with Locally Advanced/Unresctable Pancreatic Cancer. Proc ASCO 18: #788, 205a, 1999

48. Mc Clay EF, Mc Clay ME, Monroe L, Baron P, Cole D, O’Brien P, Metcalf J,

Maize J: The effect of tamoxifen (TAM) and cisplatin (DDP) on the disease free survival (DFS) and overall survival (OS) in patients with high risk melanoma. The 3rd International Conference on The Adjuvant Therapy of Malignant Melanoma, Royal College of Physicians, London, United Kingdom #23, pg 24, 1999

49. Phelps R., Mc Clay E., Knebel G., Dahm M.:Telomerase-A suitable marker for

circulating tumor cells in peripheral blood of melanoma patients. ASCB, San Francisco, 2000

Edward F. McClay

50. Witkiewicz H., Los G., Mc Clay E F,: Peroxisome proliferator activated

receptors (PPAR) g1 and g2 transcripts in cultured human melanoma cells. Proc AACR 42: #510, 94, 2001

51. Spear MA, Mirmiran A, Mc Clay E.:Phase I/II trial of IV topotecan (TOPO) in

combination with whole brain radiation therapy (WBXRT). PROC ASCO 23 #1553, 120, 2004

52. Dillman RO, Selvan SR, Schiltz PM, Allen K, Depriest C, McClay EF, Barth

NM, Sheehy PF, DeLeon C, Peterson C, Beutel LD:Pure autologous tumor cells (TC) and dendritic cells (DC) with GM-CSF: patient-specific vaccine for metastatic melanoma. PROC ASCO 23 #7547, 718, 2004

53. McClay EF, Bessudo A, Frakes l, Eisenberg S, Just R, Banerjee P, Sinclair J: A

Phase I/II Trial of the combination of bevacizumab, oxaliplatin and sorafenib in patients with metastatic melanoma. PROC ASCO 2008 submitted

54. Mita R, Heist R, Aren O, Mainwaring P. Bazhenova L, Gadgeel S, Blum R, Polikoff J, Biswas J, McClay E, Ross H, Mohan R, Reich SD, Neuteboom S, Lloyd GK, Spear MA:Randomized phase 2 study of docetaxel +/- plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC) (ADVANCE). PROC ASCO 2010

55. Dillman RO, Cornforth AC, DePriest C,1 McClay EF, Armatruda TT, Carbonell

D,1 De Leon C,1 Mayorga C, Ellis R: Randomized trial of autologous dendritic cell and tumor cell vaccines in patients with metastatic melanoma. PROC ASCO 2011

56. Dillman RO, Cornforth AN, DePriest C, McClay EF, Amatruda TT, Carbonell D,

De Leon C, Mayorga C, Ellis R:Randomized tiral of autologous tumor cell vaccines in patients with metastatic melanoma. Society for the Immunotherpay of cancer (SITC) 11/4/11

57. Dillman RO, DePriest C, De Leon C, Barth NM,1 McClay EF, Amatruda TT,

Schwartzberg L, Sheehy PF, Mahdavi KM, Mayorga C, Ellis R: Patient-specific active specific immunotherapy utilizing putative tumor cells in patients with metastatic melanoma: a pooled analysis comparing tumor cell and dendritic cell vaccines from two phase II trials and a randomized phase II trial. J Clin Oncol 30, 2012 (suppl; abstr 2569)

Publications 1. Merli GJ, Hojat M, Gonnella J, Mc Clay EF, Fellin F, DeCaro M, Martin J.

Physicians test ordering behavior as a function of justification of the test. Proc Annu Conf Res Med Educ 24: 167-72, 1985

Edward F. McClay

2. Merli GJ, Weitz HH, Martin JH, Mc Clay EF, Adler AG, Fellin FM, Libonati M.

Cardiac dysrythmias associated with ophthalmic atropine. Arch Intern Med 146:45-47, 1986.

3. Kane M, Mc Clay EF, Bellet RE. Frequency of occult residual melanoma

following excision of a clinically positive regional lymph node. Ann Surg 205:88-89, 1987

4. Mc Clay EF, Lusch, CJ, Mastrangelo MJ. Allergy induced hepatic toxicity

associated with DTIC (Dacarbazine). Cancer Treat Rep 71(2):219-220, 1987. 5. Mc Clay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination

chemo/hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71(5):465-469, 1987

6. Mc Clay EF, Berd D, Mastrangelo MJ, Bellet RE. Letter to the Editor: Adjuvant

therapy for breast cancer. NEJM 319(7):443, 1988. 7. Mc Clay EF, Mastrangelo MJ. Systemic chemotherapy for metastatic melanoma.

Sem Onc 15 (6):569-577, 1988 8. Mc Clay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance

of Tamoxifen to a cisplatin containing regimen in the treatment of metastatic melanoma. Cancer 63:1292-1295, 1989.

9. Mc Clay EF. Epidemiology of bone and soft tissue sarcomas. Sem Onc

16(4):264-272, 1989. 10. Mc Clay EF, Slovin SF. Immunotherapeutic approaches to the treatment of bone

and soft tissue sarcomas. Sem Onc 16(4):328-332, 1989. 11. Mc Clay EF, Howell SB. Intraperitoneal Cisplatin in the Management of

Patients with Ovarian Cancer: A Review. Gynecol Oncol 36:1-6, 1990. 12. Norton FL, Shuey S, Morton DL, Mittleman A, Ferrone S, Mitchell MS, Mc Clay

EF, Kohler H. Response to anti-idiotype in scid mice reconstituted with lymphoid cells from melanoma patients. Cellular Immunity and the Immunotherapy of Cancer 135:361-369, 1990.

13. Isonishi S, Kirmani S, Kim S, Plaxe S, Braly P, Mc Clay EF, Howell SB. Phase

I and pharmacokinetics trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. JNCI 83:621-626, 1991.

14. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW, Longo DL, Gould B,

Frankel A, Mc Clay EF, Howell S, Reed E, Willingham MC, Fitzgerald DJ,

Edward F. McClay

Pastan I. Clinical evaluation of intraperitoneal pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. Journal of Clinical Oncology 9:2095-2103, 1991.

15. Mc Clay EF, Hunger K. Melanoma: New Biology, New Therapy. Critical

Reviews in Oncology/Hematology. 11:299-314, 1991. 16. Howell SB, Kirmani S, Mc Clay EF, Kim S, Braly P, Plaxe S. Intraperitoneal

cisplatin-based chemotherapy for ovarian carcinoma. Semin Oncol 18 (1Suppl 3):5-10, 1991

17. Mc Clay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective Combination

Chemo/Hormonal Therapy for Malignant Melanoma: Experience with Three Consecutive Trials. Int. J. Cancer 50: 553-556, 1992.

18. Fishbein GE, Mc Clay EF, Berd D, Mastrangelo MJ. A post surgical adjuvant

trial of CEA immunization in patients with Dukes C and D colorectal cancer: a pilot study. Vaccine Res 1:123-128, 1992.

19. Mc Clay EF, Christen R, Albright KA, Jones JA, Eastman A, Howell SB.

Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Research 52:6790-96, 1992.

20. Goel R, Mc Clay EF, Kirmani S, Kim S, Braly PD, Plaxe SC, Alcaraz J,

Andrews PA, Reichman B, Markman M, Howell SB. Pharmacokinetics study of Intraperitoneal Streptozotocin. Clin. Invest. Med. 15:420-426, 1992.

21. Mc Clay EF, Albright KD, Jones JA, Christen R, Howell SB. Tamoxifen

modulation of Cisplatin Sensitivity In Human Malignant Melanoma Cells. Cancer Res 53(7):1571-1576, 1992.

22. Bonetti A, Howell SB, Mc Clay EF, Kirmani S, Goel R, Plaxe S, Braly P, Kim S.

High-dose biweekly Intraperitoneal Cisplatin: An Effective Way to Increase Cisplatin Dose Intensity. Gynec. Oncol 49:318-324, 1993.

23. Kim S, Howell SB, Mc Clay EF, Kirmani S, Goel R, Plaxe S, Braly P, Bonetti A.

Dose Intensification of Cisplatin Chemotherapy through Biweekly Administration. Ann Oncol 4(3):221-227, 1993.

24. Mc Clay EF, Goel R, Andrews, PA, Gorelick, S, Kirmani S, Kim S, Braly P,

Plaxe S, Hoff S, Alcaraz, J, Howell SB. A Phase I and Pharmacokinetic Study of Intraperitoneal Carboplatin and Etoposide. Br. J. Cancer 68:783-788, 1993.

25. Plaxe SC, Braly PS, Freddo JL, Mc Clay EF, Kirmani S, Howell SB. Profiles of

women age 30-39 and age less than 30 with epithelial ovarian cancer. Obs. Gynec 81 [5(pt1)]:651-656, 1993

Edward F. McClay

26. Mc Clay EF, McClay ME, Albright KA, Jones JA, Christen R, Alcaraz J, Howell

SB. Tamoxifen Modulation of Cisplatin Resistance in Patients with Metastatic Melanoma: A biologically important observation. Cancer 72:1914-1918, 1993.

27. Christen RD, Mc Clay EF, Kim S, Kirmani S, Plaxe SC, Braly PD, Heath DD,

Schlinsky DR, Wang J, Yen SCC, Howell SB: In-vivo modulation of doxorubicin by high-dose progesterone. A phase I pharmacokinetic study. J Clin Oncol 11:2417-2426, 1993

28. Mc Clay EF, Albright KD, Jones JD, Christen R, Howell SB: Tamoxifen

modulation of cisplatin cytotoxicity in human malignancies. Int J. Cancer 55:1018-1022, 1993.

29. Plaxe SC, Braly PS, Freddo JL, Mc Clay EF, Christen RD, Kirmani S, Kim S,

Heath D, Howell SB: Phase I and pharmacokinetic study of intraperitoneal ormaplatin. Gynecol Oncol 51:72-77, 1993.

30. Mc Clay EF, McClay, ME:Tamoxifen: Is it useful in the treatment of patients

with metastatic melanoma ? J Clin Oncol 12:617-626, 1994 31. Christen, RD, Mc Clay EF:Circumventing multidrug resistance. Contemporary

Oncology 4:48-57, 1994 32. Mc Clay EF, Braly P, Kirmani S, Kim S, Plaxe S, Wilgus L, McClay ME,

Howell SB: A phase I study of high-dose intraperitoneal Carboplatin and Etoposide in patients with intra-abdominal malignancies with GM-CSF support. Cancer 74:664-669,1994

33. Mc Clay EF, Albright KA, Jones JD, Christen RD, Howell SB: Tamoxifen delays

the development of resistance to cisplatin in human malignancies. Br J Cancer 70:449-452, 1994

34. Jones JA, Gately DP, Barton RM, Los G, Albright KD, Christen RD, Mc Clay

EF, Howell SB: Induction of GADD1 153 in human melanoma xenografts as an indicator of genotoxic injury. Cellular Pharm. 1:233-237, 1994

35. Kirmani S, Braly PS, Mc Clay EF, Saltzstein SL, Plaxe SC, Kim S, Cates C,

Howell SB: A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54:338-344, 1994

36. Plaxe SC, Freddo J, Kim S, Kirmani S, Mc Clay EF, Christen R, Braly PS,

Howell SB: Phase I trial of cisplatin in combination with glutathione. Gynecol Oncol 55:82-86, 1994

Edward F. McClay

37. Mc Clay EF, Braly P, Kirmani S, Plaxe S, Kim S, McClay ME, Wilgus L, Howell SB: A phase II study of intraperitoneal carboplatin and etoposide with GM-CSF support in patients with ovarian cancer. Am J Clin Oncol 18:23-26, 1995.

38. Mc Clay EF, McClay MET. Systemic Chemotherapy for the Treatment of

Metastatic Melanoma. Sem Onc 23:744-753, 1996 39. Mc Clay EF, Jones JA, Albright KA, Winski PJ, Christen RD, Howell SB:

Determinants of Tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res 56: 3993-3997, 1996

40. Mc Clay EF, Winski PJ, Jones JA, Jenrette, III, JM, Gattoni-Celli S.:∆12-

Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation. Cancer Res 56:3866-3869, 1996

41. Mc Clay EF, McClay ME, Jones JA, Winski PJ, Christen RD, Howell SB, Hall

PD: A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Cancer 79:1037-1043, 1997

42. Jones JA, Albright KD, Christen RD, Howell SB, Mc Clay EF: Synergy between

tamoxifen and cisplatin in human melanoma cells is dependent upon the presence of antiestrogen binding sites. Cancer Research 57:2657-2660,1997

43. Cole DJ, Gattoni-Celli S, Mc Clay EF, Metcalf J, Brown JM, Nabavi N, Newton,

III, DA, Woolhiser CB, Wilson MC, Vournakis J: Characterization of a sustained release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine based polymer matrix. Clin Cancer Res 3:867-873, 1997

44. Plaxe SC, Christen RD, O’Quigley J, Braly PS, Freddo JL, Mc Clay EF, Heath

D, Howell SB: Phase I and pharmacokinetic study of intraperitoneal topotecan. Investigational New Drugs 16(2): 147-53, 1998

45. Aebi S, Schnider TW, Los G, Health D, Darrah D, Kirmani S, Mc Clay EF,

D’Agostino H, Plaxe SC, Fink D, de las Alas M, Howell SB, Christen RD: A phase II pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemotherapy and Pharmacology 44(3): 259-65, 1999

46. Mc Clay EF, Jones JA: Characterization of a human melanoma cell line with

non-estrogen receptor tamoxifen resistance. Melanoma Research 9:531-537, 1999 47. de las Alas M, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S,

D’Agostino HR, Plaxe SC, Darrah D, Mc Clay EF, Aebi S, Howell SB, Los G.: Increase in Tumor GADD153 mRNA Level Following Treatment Correlates with Response to Paclitaxel. Cancer Chemotherapy and Pharmacology, 45(5): 381-388, 2000

Edward F. McClay

48. Mc Clay EF, Mc Clay ME, Monroe L, Baron PL, Cole DJ, O’Brien PH, Metcalf

JS, Maize JC : The Effect of Tamoxifen and Cisplatin on the Disease Free and Overall Survival of Patients with High-Risk Malignant Melanoma. British Journal of Cancer 83(1): 16-21, 2000

49. Mc Clay EF: The Effects of ∆12-PGJ2 on Malignant Cells. Prostaglandins &

Other Lipid Mediators 62: 75-90, 2000 50. Mc Clay EF, Mc Clay MET, Monroe L, Jones JA, Winski P: A Phase II Study of

High Dose Tamoxifen and Weekly Cisplatin in Patients with Metastatic Melanoma. Melanoma Research 11:309-313, 2001

51. Nguyen, C.L., Mc Clay, E.F., Cole, D.J., O’Brien, P.H., Gillanders, W.E.,

Metcalf, J.S., Maize, J.C., Baron, P.L.: Melanoma thickness and histology predict sentinel lymph node status. Am J Surgery. 181:8-11, 2001

52. Parhizkar, N., Jones, VE., McClay EF,. Yi ES., Bouvet M.: Metastatic melanoma

in a patient with Clouston Syndrome successfully treated with isolated limb perfusion. J Cutan Med Surg 7:43-46, 2003

53. McClay EF.: Adjuvant therapy for patients with high-risk malignant melanoma.

Semin Oncol 29:389-399, 2002 54. Li Y., McClay EF.: Systemic chemotherapy for the treatment of metastatic

melanoma. Semin Oncol 29:413-426, 2002 55. McClay EF, Maio M.: Introduction: Melanoma: American and European

perpsectives on diagnosis and treatment. Semin Oncol 29:306-307, 2002. 56. Dillman RO, Selvan SR, Schiltz PM, Allen K, Depriest C, McClay EF, Barth

NM, Sheehy PF, DeLeon C, Peterson C, Beutel LD:Phase I/II trial of patient-specific vaccine of proliferating autologous tumor cells, dendritic cells and GM-CSF: Planned interim analysis. Cancer Biotherapy and Radiopharmaceuticals19:658-665 2004

57. Mc Clay EF, Bogart J, Herndon II JE, Watson D, Evans L, Seagran SL, Green

MR: A phase III trial evaluating the combination of cisplatin, etoposide and radiation therapy with or without tamoxifen in patients with limited stage small cell lung cancer: Cancer and Leukemia Group B Study (9235) Amer J Clin Oncol 28: 81-90 2005

58. Mirmiran A, McClay EF, Spear MA: Phase I/II study of IV topotecan in

combination with whole brain radiation for the treatment of brain metastases. Med Oncol 24(2) 147-153, 2007

Edward F. McClay

59. Bogort JA, Watson D, McClay EF, Evans L, Herdon JE, Laurie F, Segrean SL, Fitzgerald TJ, Vokes E, Green MR: Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer 62(1): 92-98, 2008

60. Dillman R, Selvan S, Schlitz PM, McClay E, Barth NM, DePreist C, deLeon C,

Mayorga C, Conforth AN, Allen K: Phase II trial of dendritic cells loaded with antigens from self-renewing proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: a final report. Cancer, Biother and Radiopharma 24, 311-319 2009

61. Lamont EB, Landrum MB, Archer L, Lan L, Strauss GM, Lilenbaum R, Niel HB,

Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, Keating NL, McNeil BJ For the Cancer and Leukemia Group B: Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol 28:215-21, 2010

62. Dillman RO, Cornforth AN, DePriest C, McClay EF, Amatruda TT, de Leon C,

Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.J Immunother. 2012 Oct;35(8):641-9.

63. Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson Jr. JJ,

Frank R, Shore, ND Dreicer R, McClay EF, Berry WR, Agrawal M, Rotshteyn Y Stambler, N Olson WC, Morris SA, Israel RJ: Phase 1 Study of PSMA ADC, an Antibody-drug Conjugate Targeting Prostate-specific Membrane Antigen, in Chemotherapy-refractory Prostate Cancer, Clin Can Res Subnitted 2013

64. Dillman RO, McClay EF, Barth NM, Amatruda, T, Schwartzberg LS, Mahdavi

K,, Sheehy FP, DePriest C:Dendritic cell versus tumor cell presentation of autologous antigens for patient-specific, active specific immunotherapy: impact on long-term survival in metastatic melanoma patients with either no evidence of disease or detectable metastases at the time of treatment. Society for the Immunotherapy of Cancer submitted 2013

Book Chapters 1. Mc Clay EF. The Healthy Patient. In: Adler AF, Preoperative Evaluation the

Surgical Patient. Philadelphia, PA: WB Saunders, 204-212, 1984. 2. Mc Clay EF, Bellet RE. Preoperative Evaluation of the Oncology Patient. In:

Merli GJ, Weitz HT (eds), Preoperative Evaluation, Medical Clinics of North

Edward F. McClay

America. Vol 71 (3), Philadelphia, PA: W.B. Saunders, 529-540, May 1987. 3. Mc Clay EF. Strategies in the surgical patient with cancer. In: Merli GJ, Weitz

HH. Medical Care of the Surgical Patient. (eds) WB Saunders, Philadelphia, PA pg 295-318, 1992

4. Mc Clay EF, Howell SB: Intraperitoneal chemotherapy for ovarian cancer. In

Hematology/Oncology Clinics of North America, Ovarian Cancer. Ozols RF (eds) WB Saunders, Philadelphia, PA 915-926, 1992

5. Mc Clay EF. Strategies in the surgical patient with cancer. In: Merli GJ, Weitz

HH. (2nd Edition) Medical Care of the Surgical Patient. WB Saunders, Philadelphia, PA 263-282, 1998

6. McClay EF,: Chapter 3 Taxanes and Epothilones in Cancer Treatment. Cancer

Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Meausures; Cancer Growth & Progression, Volume 13 Boris Minev Ed; Professor Hans Kaiser Series Editor pg 39-60, 2011,

Guest Editor 1. Mc Clay EF. Bone and soft tissue sarcomas. Guest Editor. Sem Onc 16(4):263-

334, 1989. 2. Mc Clay EF. Malignant Melanoma. Guest Editor Seminars in Oncology

23(6):649-781, 1996 3. McClay EF, Maio M. Guest Editor, Melanoma I: American and European

perspectives on diagnosis and treatment. Semin Oncol 29 August 2002 4. McClay EF, Maio M. Guest Editor, Melanoma II: American and European

perspectives on diagnosis and treatment. Semin Oncol 29 October 2002 Books 1. Mc Clay EF, Mc Clay MET, Smith J.: 100 Questions and Answers About

Malignant Melanoma and Other Skin Cancers J&B Publishers, Boston, MA, May, 2003

2. Mc Clay EF, Mc Clay MET, Vassiliadis C, Roberts J:100 Questions and

Answers About Malignant Melanoma and Other Skin Cancers, 2nd edition J&B Publishers, Boston, MA, 2013 In Press

Invited Commentary/Articles/Editorials 1. Mc Clay EF, Berd D, Mastrangelo MJ: Editorial; The Dartmouth Regimen: Gone

or Going Strong? Cancer Invest. 16, 421-423, 1998

Edward F. McClay

2. McClay EF (Team Leader), Easter D, O’Grady T, Petzinger T:

Multidisciplinary Management in Primary and Metastatic Melanoma, Vindico Medical Education Monograph October 10, 2008

3. Berger AC, McClay EF, Toporcer M, Wolchok JD, Morris GJ:Completely

regressed cutaneous melanocytic lesion: was it benign or malignant? Current Clinical Practice Semin Oncol 36(5): 375-9, 2009

4. Feeney K, Maguire Jr. HC, McClay EF, Sato T, Sonsak VK, Toporcer M, Zager

JS: Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease. Are there safe and potentially effective treatments? Current Clinical Practice Semin Oncol 37 (4): 303-12, 2010

5. McClay EF: Role of anti-TNF compounds in the development of malignant

melanoma, Current Clinical Practice Semin Oncol. 2010 Jun;37(3):188-9. 6. McClay EF: Thin (< 1 mm depth) Melanomas: The Dilemma of Defining

Management and Counseling Prognosis; Current Clinical Practice Semin Oncol 2013 In Press

Patents 5,844,001 Combination Platinum Chemotherapeutic/Antiestrogen December 1, 1998 Therapy for Human Cancers 5,877,215 Method of Treating Neoplastic Cells with Prostaglandin March 2, 1999 and Radiation Treatment or Prostaglandin and Platinum- based Anti-Tumor Agents 6063375 Semiallogeneic Cell Hybirds and Related Methods for May 16, 2000

Treating Cancer 6,288,111 B1 Combination Cisplatin/Tamoxifen Therapy for Human September 11, 2001 Cancers.

institute for melanoma research & education › app › uploads ›...

Documents